Navigation Links
Oncolytics Biotech Inc. Completes Patient Enrolment in U.K. Phase Ia/Ib Combination REOLYSIN(R)/Radiation Clinical Trial
Date:12/21/2007

otech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the Phase 1a/Ib U.K. combination REOLYSIN(R) and radiation clinical trial, and the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN(R) as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN(R), uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... (PRWEB) April 30, 2015 Available ... at http://www.lespausa.com , Fleur’s ... product combining the benefits of makeup, skin care ... subtly tinted cream is designed with specific complexion-correcting ... an even complexion and a healthy glow. Far ...
(Date:4/30/2015)... Cordova, CA (PRWEB) April 30, 2015 ... announced that Julie I. Morris has joined SureClinical’s executive ... is an experienced biotech and technology executive with over ... large Fortune 500 companies. , Ms. Morris joins ... ag biotech company. She was CFO of MBI from ...
(Date:4/30/2015)... 2015 Sterlitech is proud to ... PX, PY, and PZ Polyacrylonotrile (PAN) membranes ... Designed to be ideal for oil removal ... fill critical process requirements where the presence of ... “New regulations on industrial wastewater discharge and quality ...
(Date:4/29/2015)... BELLINGHAM, Washington, and BALTIMORE, Maryland, USA (PRWEB) April 29, ... premier event for photonics, optical sensing, and imaging on ... a place for government program managers, researchers, applications developers, ... and technology of sensing and imaging for multiple applications. ... -- defense and security, and commercial and scientific sensing ...
Breaking Biology Technology:Fleur’s Introduces CC CRÈME Perfect Skin Solution 2Fleur’s Introduces CC CRÈME Perfect Skin Solution 3Julie I. Morris Joins SureClinical as Chief Financial Officer 2Sterlitech Offers New Ultrafiltration Membranes 2SPIE DSS provides venue for collaboration vital to research, applications advances 2SPIE DSS provides venue for collaboration vital to research, applications advances 3SPIE DSS provides venue for collaboration vital to research, applications advances 4
... CGCP), announced that the company will release results,for ... to market open on,Wednesday, November 14, 2007. The ... Senior Vice President and Chief Financial Officer William ... day at 12:00 p.m. Eastern,time (9:00 a.m. Pacific ...
... Oct. 24 Cell Therapeutics,Inc. (CTI) (Nasdaq ... at,the 19th annual AACR-NCI-EORTC Symposium show its ... refractory to currently,marketed platinum agents carboplatin, cisplatin ... trials in late 2008. "Bis-platinates represent ...
... /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) ... of approval from the U.K. Medicines and ... Trial Application (CTA) to begin,a clinical trial ... cyclophosphamide, a chemotherapeutic agent as well as,immune ...
Cached Biology Technology:Cardiogenesis Corporation to Report Third Quarter 2007 Results on November 14th 2First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs 2First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs 3Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide 2Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide 3
(Date:4/1/2015)... , April 1, 2015   Medisafe ™, the ... users across iOS and Android ... integrating biofeedback into the platform to allow patients to ... For the first time, patients will be able to ... dose impacts important biometrics, such as glucose levels and ...
(Date:3/24/2015)... , Mar. 24, 2015 Research and Markets ... of the "Global Iris Recognition Market 2015-2019" ... the Global Iris Recognition market to grow at a ... This report covers the present scenario and the ... the period 2015-2019. To calculate the market size, the ...
(Date:3/23/2015)... , March 23, 2015   HOYOS Labs , ... company, today announced that the Company will demonstrate multiple ... enterprise and consumers at Connect:ID on March 23 through ... HOYOS Labs will highlight the IEEE Biometric Open Protocol ... ; and enterprise access control system. BOPS was invented ...
Breaking Biology News(10 mins):Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3
... of how plants "breathe" may help us breed and select ... of Toronto study. , The paper, which offers the first ... surface pores, appears in the July 12 issue of Current ... and senior author Malcolm Campbell. "This is a gene that ...
... intense selective logging stopped in the region now ... guenon (Cercophithecus ascanius) is a primate still in ... new study, changed the ecological balance for these ... door for multiple parasitic infections. , The researchers ...
... sneak past the blood brain barrier, which protects the brain ... particularly invasive brain cancer, according to a new Saint Louis ... Academy of Sciences Online Early Edition the week of Aug. ... drugs into the brain, you can cure brain cancer," says ...
Cached Biology News:Genetic discovery could lead to drought-resistant plants 2Logging changed ecological balance for monkeys, damaged health 2Logging changed ecological balance for monkeys, damaged health 3Slipping past the blood brain barrier: Research shows potential treatment for brain cancer 2
Request Info...
... are cytopathic effect inhibition assays, also known as ... tissue culture supernatents; serum from PK studies and ... is defined as the quantity of interferon required ... viral infection by 50%. All standards ...
supplied with 10x reaction buffer...
... bioassays for interferons are cytopathic effect inhibition assays, ... Sample types include; tissue culture supernatents; serum from ... assays, one unit is defined as the quantity ... cytopathic effect of viral infection by 50%. ...
Biology Products: